JP2014527407A - 網膜変性疾患の処置方法 - Google Patents

網膜変性疾患の処置方法 Download PDF

Info

Publication number
JP2014527407A
JP2014527407A JP2014523346A JP2014523346A JP2014527407A JP 2014527407 A JP2014527407 A JP 2014527407A JP 2014523346 A JP2014523346 A JP 2014523346A JP 2014523346 A JP2014523346 A JP 2014523346A JP 2014527407 A JP2014527407 A JP 2014527407A
Authority
JP
Japan
Prior art keywords
cells
cell
retinal
wnt
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014523346A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014527407A5 (cg-RX-API-DMAC10.html
Inventor
マリア、ピア、コズマ
ダニエラ、サンヘス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daniela Sanges
Original Assignee
Daniela Sanges
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daniela Sanges filed Critical Daniela Sanges
Publication of JP2014527407A publication Critical patent/JP2014527407A/ja
Publication of JP2014527407A5 publication Critical patent/JP2014527407A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2014523346A 2011-08-05 2012-08-06 網膜変性疾患の処置方法 Pending JP2014527407A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11176713.3 2011-08-05
EP11176713A EP2554662A1 (en) 2011-08-05 2011-08-05 Methods of treatment of retinal degeneration diseases
PCT/EP2012/065327 WO2013020945A1 (en) 2011-08-05 2012-08-06 Methods of treatment of retinal degeneration diseases

Publications (2)

Publication Number Publication Date
JP2014527407A true JP2014527407A (ja) 2014-10-16
JP2014527407A5 JP2014527407A5 (cg-RX-API-DMAC10.html) 2016-01-21

Family

ID=46826437

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014523346A Pending JP2014527407A (ja) 2011-08-05 2012-08-06 網膜変性疾患の処置方法

Country Status (15)

Country Link
US (1) US20140199277A1 (cg-RX-API-DMAC10.html)
EP (2) EP2554662A1 (cg-RX-API-DMAC10.html)
JP (1) JP2014527407A (cg-RX-API-DMAC10.html)
KR (1) KR20140068936A (cg-RX-API-DMAC10.html)
CN (1) CN104011203A (cg-RX-API-DMAC10.html)
AR (1) AR087471A1 (cg-RX-API-DMAC10.html)
AU (1) AU2012293681A1 (cg-RX-API-DMAC10.html)
BR (1) BR112014002718A8 (cg-RX-API-DMAC10.html)
CA (1) CA2844106A1 (cg-RX-API-DMAC10.html)
CO (1) CO7081142A2 (cg-RX-API-DMAC10.html)
IL (1) IL230830A0 (cg-RX-API-DMAC10.html)
MX (1) MX2014001475A (cg-RX-API-DMAC10.html)
RU (1) RU2014108478A (cg-RX-API-DMAC10.html)
SG (1) SG2014008080A (cg-RX-API-DMAC10.html)
WO (1) WO2013020945A1 (cg-RX-API-DMAC10.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013045694A1 (en) 2011-09-29 2013-04-04 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Compositions and methods for the treatment of degenerative retinal conditions
SG11201605833PA (en) 2014-01-17 2016-08-30 Sumitomo Chemical Co Method for manufacturing ciliary margin stem cells
IL251178B (en) * 2014-09-16 2022-07-01 Genzyme Corp Adeno-associated viral vector for the treatment of glaucoma myocilin (myoc)
RU2569481C1 (ru) * 2014-12-25 2015-11-27 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ получения культуры клеток ретинального пигментного эпителия из глаза взрослого донора-трупа
RU2578526C1 (ru) * 2014-12-25 2016-03-27 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ получения органной культуры хороидально-пигментного комплекса из глаза взрослого донора-трупа
KR101779932B1 (ko) * 2015-09-15 2017-09-21 주식회사 스템랩 나노그(Nanog)를 도입한 양수 내 태아 유래 중간엽 줄기세포를 이용한 육모 촉진용 조성물의 제조방법
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
KR101674622B1 (ko) * 2016-07-07 2016-11-09 국민대학교산학협력단 세스퀴테르펜 유도체의 신규한 용도
EP3484463B1 (en) * 2016-08-19 2020-02-12 The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology Transfer Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
EP3535282A4 (en) * 2016-11-06 2020-04-08 Nanoscope Technologies LLC OPTOGENETIC MODULATION BY OPSINS WITH MULTIPLE CHARACTERISTICS FOR RESTORATION OF VISION AND OTHER ASSOCIATED APPLICATIONS
JP2020518915A (ja) 2017-04-27 2020-06-25 パスハラキス スタブロスＰＡＳＣＨＡＬＡＫＩＳ， Ｓｔａｖｒｏｓ 自動眼底画像分析用のシステムおよび方法
AR111808A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
PE20191787A1 (es) 2017-05-18 2019-12-24 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituidos
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
KR102612140B1 (ko) 2017-05-18 2023-12-08 이도르시아 파마슈티컬스 리미티드 피리미딘 유도체
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
JP7376092B2 (ja) * 2017-06-15 2023-11-08 ザ ユニバーシティ オブ ノース テキサス ヘルス サイエンス センター アット フォート ワース 網膜細胞への線維芽細胞の再プログラミング方法
CN117159463A (zh) * 2017-08-20 2023-12-05 加州大学董事会 治疗青光眼的Wnt5a的调节
US20220040236A1 (en) * 2018-04-06 2022-02-10 Icahn School Of Medicine At Mount Sinai Compositions and methods of treatment of vision loss through generation of rod photoreceptors from müller glial cells
EP3937955A4 (en) * 2019-03-15 2022-12-07 The Schepens Eye Research Institute, Inc. ISOLATION, ENHANCEMENT AND EXPANSION OF CONICAL PROGENITOR CELLS AND THEIR USES
CN110706164A (zh) * 2019-09-03 2020-01-17 北京爱博同心医学科技有限公司 基于增强现实的管状视野图像变形显示方法及眼镜
US12558336B2 (en) 2019-09-25 2026-02-24 The Board Of Trustees Of The Leland Stanford Junior University Metabolic rescue of retinal degeneration
KR20210119766A (ko) * 2020-03-25 2021-10-06 서울대학교병원 인간 배아줄기세포 유래 중간엽 줄기세포를 포함하는 망막색소변성의 예방 또는 치료용 약학적 조성물
KR102655748B1 (ko) * 2023-06-08 2024-04-05 충북대학교 산학협력단 고포도당 조건에서의 중간엽 줄기세포의 생존율을 증가시키는 방법
KR102655735B1 (ko) * 2023-06-09 2024-04-05 충북대학교 산학협력단 당뇨성 망막병증의 예방 및 치료를 위한 타크로리무스 전처리 줄기세포
TW202604507A (zh) 2024-05-02 2026-02-01 瑞士商愛杜西亞製藥有限公司 經n-取代之吲哚衍生物的結晶形式

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060147435A1 (en) * 2004-12-30 2006-07-06 Moon Randall T Methods for regulation of stem cells
JP2008512376A (ja) * 2004-09-03 2008-04-24 ザ・スクリプス・リサーチ・インステイチユート 単離された系統陰性造血幹細胞及びこれを用いた治療方法
JP2009500297A (ja) * 2005-06-08 2009-01-08 セントカー・インコーポレーテツド 眼の変性についての細胞療法
JP2010509916A (ja) * 2006-11-16 2010-04-02 ザ スクリップス リサーチ インスティテュート 単離された骨髄球様細胞集団及びそれを用いた治療方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6128654A (en) 1997-02-14 2000-10-03 Advanced Micro Devices, Inc. Method and apparatus for transmitting multiple copies by replicating data identifiers
DE69919707T2 (de) 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
CN1272328C (zh) 1999-12-17 2006-08-30 希龙公司 糖元合成酶激酶3的基于吡嗪的抑制剂
ES2246927T3 (es) 1999-12-17 2006-03-01 Chiron Corporation Inhibidores biciclicos de glucogeno sintasa quinasa 3.
WO2002020495A2 (en) 2000-09-06 2002-03-14 Chiron Corporation Inhibitors of glycogen synthase kinase 3
BRPI0113757B8 (pt) 2000-09-11 2017-11-07 Chiron Corp derivados de quinolinona como inibidores de tirosina quinase
WO2002096905A1 (en) 2001-06-01 2002-12-05 Vertex Pharmaceuticals Incorporated Thiazole compounds useful as inhibitors of protein kinases
KR20040084896A (ko) 2002-02-06 2004-10-06 버텍스 파마슈티칼스 인코포레이티드 Ｇｓｋ-3의 억제제로서 유용한 헤테로아릴 화합물
EP1490093A4 (en) 2002-03-01 2007-04-11 Novartis Vaccines & Diagnostic METHOD AND COMPOSITIONS FOR TREATING ISCHEMIA
US7838290B2 (en) * 2002-07-25 2010-11-23 The Scripps Research Institute Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
US20050129665A1 (en) 2002-07-25 2005-06-16 Martin Friedlander Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
CA2496246A1 (en) 2002-08-23 2004-03-04 Chiron Corporation Pyrrole based inhibitors of glycogen synthase kinase 3
CN1717391A (zh) 2002-10-21 2006-01-04 希龙公司 糖元合成酶激酶3的抑制剂
CA2524063C (en) * 2003-05-02 2015-02-17 The Scripps Research Institute Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
JP2007502300A (ja) 2003-08-13 2007-02-08 カイロン　コーポレイション Ｇｓｋ−３インヒビターおよびその使用
RU2403906C2 (ru) 2005-02-24 2010-11-20 Дзе Скриппс Рисерч Инститьют Способ лечения ретинопатии при недоношенности и родственных ретинопатических заболеваний
US8354370B2 (en) * 2007-06-15 2013-01-15 Garnet Biotherapeutics, Inc. Administering a biological composition or compositions isolated from self-renewing colony forming somatic cell growth medium to treat diseases and disorders
EP2090649A1 (en) 2008-02-13 2009-08-19 Fondazione Telethon Method for reprogramming differentiated cells
GB0816577D0 (en) * 2008-09-11 2008-10-15 Axordia Ltd Growth factor
EP2486126B1 (en) * 2009-10-06 2017-12-06 SNU R & DB Foundation Method for differentiation into retinal cells from stem cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008512376A (ja) * 2004-09-03 2008-04-24 ザ・スクリプス・リサーチ・インステイチユート 単離された系統陰性造血幹細胞及びこれを用いた治療方法
US20060147435A1 (en) * 2004-12-30 2006-07-06 Moon Randall T Methods for regulation of stem cells
JP2009500297A (ja) * 2005-06-08 2009-01-08 セントカー・インコーポレーテツド 眼の変性についての細胞療法
JP2010509916A (ja) * 2006-11-16 2010-04-02 ザ スクリップス リサーチ インスティテュート 単離された骨髄球様細胞集団及びそれを用いた治療方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6016011403; ＩＮＯＵＥ　Ｔ．　ｅｔ　ａｌ．: ＳＴＥＭ　ＣＥＬＬＳ Ｖｏｌ．２４, 2006, ｐ．９５-１０４ *
JPN6016011405; ＯＳＡＫＡＤＡ　Ｆ．　ｅｔ　ａｌ．: Ｊ　Ｎｅｕｒｏｓｃｉ Ｖｏｌ．２７, 2007, ｐ．４２１０-２１９ *

Also Published As

Publication number Publication date
RU2014108478A (ru) 2015-09-10
MX2014001475A (es) 2014-07-22
EP2739723A1 (en) 2014-06-11
IL230830A0 (en) 2014-03-31
AR087471A1 (es) 2014-03-26
CA2844106A1 (en) 2013-02-14
WO2013020945A9 (en) 2013-04-04
WO2013020945A1 (en) 2013-02-14
US20140199277A1 (en) 2014-07-17
EP2554662A1 (en) 2013-02-06
SG2014008080A (en) 2014-03-28
NZ621345A (en) 2015-09-25
CO7081142A2 (es) 2014-10-10
BR112014002718A2 (pt) 2017-06-13
AU2012293681A1 (en) 2014-03-06
CN104011203A (zh) 2014-08-27
KR20140068936A (ko) 2014-06-09
BR112014002718A8 (pt) 2017-06-20

Similar Documents

Publication Publication Date Title
US20140199277A1 (en) Methods of Treatment of Retinal Degeneration Diseases
JP7162221B2 (ja) 網膜組織を含む細胞凝集体及びその製造方法
Sanges et al. Reprogramming Müller glia via in vivo cell fusion regenerates murine photoreceptors
JP6651440B2 (ja) 哺乳動物の網膜幹細胞の生産方法及び適用
TWI698242B (zh) 利用血管母細胞產生間葉基質細胞之方法
CN110573610B (zh) 视网膜色素上皮细胞的制备方法
JP2018518943A (ja) 幹細胞からの筋肉系列細胞の生成
JP2025028314A (ja) 網膜系細胞又は網膜組織の障害を伴う疾患の治療薬
TW201908478A (zh) 調節米勒神經膠質細胞之方法
CN118021843A (zh) 用于测量视网膜疾病疗法的疗效的方法
TW201636032A (zh) 使用前驅細胞治療眼睛病況
JP2022526591A (ja) 骨格筋幹細胞の製造及び障害の治療のための方法、組成物及びキット
WO2015125941A1 (ja) 眼疾患治療剤、そのスクリーニング方法または網膜色素上皮細胞移植に伴う拒絶反応の予測方法
TW201811344A (zh) 使用前驅細胞治療視網膜血管性疾病
KR20180088713A (ko) 전구 세포를 사용한 망막 변성의 치료
Ulrich Perspectives of stem cells: From tools for studying mechanisms of neuronal differentiation towards therapy
NZ621345B2 (en) Methods of treatment of retinal degeneration diseases
EP3231434A1 (en) Method of treatment of parkinsonism
TW202444894A (zh) 視網膜組織之製造方法
WO2022009969A1 (ja) 網膜色素上皮細胞の移植用生着促進剤
Thwaites Methods affecting neuronal differentiation of human adult and pluripotent stem cells
Jalilian Characterization of progenitors of endothelial cells (PECs)
Morad Mesenchymal stem cells: Differentiation, hematopoietic support and possible application in cell and gene therapy for osteoarthritis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150605

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160325

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161028